The authors appreciate the financial support through the “Development of nanomedicines for enzymatic replacement therapy in Fabry disease” project, granted by the Fundació Marató TV3, from the Catalan government (grant 2014SGR-1251) and Spanish Ministry of Economy and Competitiveness (MINECO) and FEDER projects (SAF2014-60138-R, CTQ2015-66194-R MINECO/FEDER). MINECO “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2015-0522) and Fundación Privada Cellex.